This study evaluated cost and utilization attributed to members enrolled in a health care program with no pharmacy co-pay. Health care savings were identified in addition to medication adherence improvements.
The management of type 2 diabetes mellitus (T2DM) remains challenging. Limitations associated with many current therapies include hypoglycemia and weight gain. An increased understanding of the pathophysiology of T2DM has led to the development of incretin-related antihyperglycemic therapies.
The cost of care for patients receiving chemotherapy in community oncology clinics is lower than for comparable patients receiving chemotherapy in the hospital outpatient setting.
The main reason given for receiving results online was time savings, reported by 77% of participants, followed by lowering the chance of missing the results (31%).
This study examines the association between cost-sharing and initiation of disease-modifying therapies among privately insured patients with multiple sclerosis.
The quality-adjusted life-year (QALY) is a popular tool for value assessment but is flawed. This paper highlights potential solutions.
Patients often self-refer to the emergency department (ED) for management of an ambulatory care–sensitive condition, and the ED may be the most appropriate care location.
Treatment of type 2 diabetes mellitus and its complications places a heavy burden on healthcare budgets in China and will continue to do so.
This report shows that a successful, cost-effective statin switch program can be implemented by a large physician group via a centralized, collaborative process.
This study shows how cardiovascular prevention would be much more efficient if risk were used in treatment decisions, but that currently it plays no role.
In this reply to the commentary, “A Call for a Statewide Medication Reconciliation Program,” published in the October 2016 issue of The American Journal of Managed Care®, authors discuss a proven and scalable solution to improve medication reconciliation that is already available to, and used by, clinicians.
This pharmacist-led, patient-directed intervention demonstrated a reduction in opioid dispensings in the 90 days following hip replacement but not knee replacement.
Pilot testing of guidelines for the laboratory monitoring of high-risk medications shows that monitoring is highly variable and that there is room for improvement.